Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Can oral NMDA blockers like Ketamir-2 disrupt current off-label CIPN treatments? Find out how MIRA Pharmaceuticals’ Ketamir-2 aims to disrupt CIPN care with oral NMDA therapy as the company targets Fast Track and prepares for Phase 2a trials. bySoujanya RaviFebruary 6, 2026